Exhibit 99.1

Lifeloc Reports Third Quarter 2021 Results

WHEAT RIDGE, Colo., October 28, 2021 -- Lifeloc Technologies, Inc. (OTC: LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the third quarter ended September 30, 2021.

Third Quarter Financial Highlights

Lifeloc posted quarterly net revenue of $1.887 million resulting in a quarterly net income of $523 thousand, or $0.21 per diluted share. These results compare to net revenue of $1.555 million and net loss of $(213) thousand, or $(0.09) per diluted share, in the third quarter of 2020. Revenue for the current quarter increased 21% versus the third quarter last year. Income for the third quarter includes the benefit from the forgiveness of the second round Paycheck Protection Program (PPP) loan of $471 thousand. For the first nine months of 2021, net revenue was $5.427 million with a net income of $816 thousand, or $0.33 per diluted share, compared to net revenue of $4.893 million and net loss of $(728) thousand, or $(0.30) per diluted share, for the same period last year. Income for the first nine months of 2021 includes the benefit from the forgiveness of the both the first and second round SBA Paycheck Protection Program (PPP) loans totaling $936 thousand. The PPP loans and forgiveness helped offset a difficult business environment in 2020 and 2021 with minimal employee disruption.

Lifeloc took advantage of continued low interest rates, refinancing our building mortgage on September 30, 2021, replacing the prior 4.00% fixed rate (until October 2024) mortgage with a 2.95% mortgage fixed until September 2031. This refinancing was immediately cash flow positive, and all refinance costs recovered through interest savings by early 2023, while eliminating the 2024 interest rate change risk from the prior mortgage.

Demand is growing for our new platform LX9 and LT7 devices. The features and performance of the new L-series products have driven penetration by meeting previously unaddressable market needs, such as wider temperature ranges and fast customization that incorporates local languages. We expect that most L-series sales will be incremental to FC-series devices rather than displacing FC sales. The L-series devices are meeting the requirements of the most modern registration standards, such as SAI’s (Standards Australia International) latest AS 3547:2019 standards for Breath Alcohol Detectors.

We continue to invest in the significant growth opportunities of alcohol monitoring and drug detection. The monitoring opportunity will be addressed primarily through the redesigned Real-Time Alcohol Detection and Reporting (R.A.D.A.R.^®) device. Manufacture of the second generation R.A.D.A.R. 200 prototype devices began in late 2020. Field testing of these redesigned R.A.D.A.R. devices and integration with the monitoring system has been extensive and has required additional modifications before final release. The design has now been finalized with several devices currently in field testing by key customers. Sales release of the R.A.D.A.R. 200 device is planned this year. Several upgrades have been made to the reporting system including migration to the cloud for higher reliability and an entirely new enrollment app to automate the enrollment process.

Our most important goal remains the convergence of the market’s need for rapid detection of drugs of abuse with Lifeloc’s capabilities. Additional personnel and new equipment resources have been committed to finalizing the development of the SpinDx™ technology platform and the rapid, quantitative marijuana breathalyzer using the SpinDx platform for detection. We have improved the detection sensitivity for delta-9-THC as well as the robustness of the device. Work continues to develop this system into a device that can be used for roadside testing, as well as other contexts requiring fast response.

“Our sales continue to recover in our core business, and our sales team is converting new customers,” commented Dr. Wayne Willkomm, President and CEO. “But our real growth driver is the strong pipeline of recent and upcoming product releases. The second generation Easycal® calibration station is yielding its best sales year ever. The L-series platform, a premium product already finding broad acceptance, is providing expanded features requested by various international law enforcement agencies. The redesigned R.A.D.A.R. 200 devices are in customers’ hands and expected to contribute revenue in the fourth quarter to begin a recurring revenue stream and fund growth. The next big milestone for Lifeloc will be completing the commercialization of the SpinDx platform – a major effort that will be prioritized over short-term profitability. We are hopeful that the SpinDx platform will begin making a revenue contribution by late 2022.”

About Lifeloc Technologies

Lifeloc Technologies, Inc. (OTC: LCTC) is a trusted U.S. manufacturer of evidential breath alcohol testers and related training and supplies for Workplace, Law Enforcement, Corrections and International customers. Lifeloc stock trades over-the-counter under the symbol LCTC. We are a fully reporting Company with our SEC filings available on our web site, www.lifeloc.com/investor.

Forward Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements expressed or implied in this press release, including statements about our strategies, expectations about new and existing products, market demand, acceptance of new and existing products, technologies and opportunities, market size and growth, and return on investments in products and market, are based on information available to us on the date of this document, and we assume no obligation to update such forward-looking statements. Investors are strongly encouraged to review the section titled “Risk Factors” in our SEC filings.

R.A.D.A.R.^® and Easycal^® are registered trademarks of Lifeloc Technologies, Inc.

SpinDx™ is a trademark of Sandia Corporation.

Amy Evans 
Lifeloc Technologies, Inc. 
http://www.lifeloc.com 
(303) 431-9500

LIFELOC TECHNOLOGIES, INC.
Condensed Balance Sheets

ASSETS
	September 30,
	2021			December 31,
CURRENT ASSETS:	(Unaudited)			2020
Cash	$	2,556,282		$	2,195,070
Accounts receivable, net		600,068			523,603
Inventories, net		2,586,117			2,498,126
Income taxes receivable		45,288			220,657
Prepaid expenses and other		89,392			77,962
Total current assets		5,877,147			5,515,418
PROPERTY AND EQUIPMENT, at cost:
Land		317,932			317,932
Building		1,928,795			1,928,795
Real-time Alcohol Detection And Recognition equipment and software		569,448			569,448
Production equipment, software and space modifications		958,785			958,785
Training courses		432,375			432,375
Office equipment, software and space modifications		216,618			216,618
Sales and marketing equipment and space modifications		226,356			226,356
Research and development equipment, software and space modifications		255,072			190,818
Less accumulated depreciation		(2,474,356	)		(2,277,839	)
Total property and equipment, net		2,431,025			2,563,288
OTHER ASSETS:
Patents, net		136,471			144,702
Deposits and other		163,480			164,798
Deferred taxes		135,215			148,142
Total other assets		435,166			457,642
Total assets	$	8,743,338		$	8,536,348
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable	$	230,572		$	333,851
Term loan payable, current portion		48,141			46,936
Paycheck Protection loan payable		—			465,097
Customer deposits		158,375			155,295
Accrued expenses		194,486			266,266
Deferred revenue, current portion		45,731			41,053
Reserve for warranty expense		46,500			46,500
Total current liabilities		723,805			1,354,998
TERM LOAN PAYABLE, net of current portion and debt issuance costs		1,280,358			1,277,531
DEFERRED REVENUE, net of current portion		4,957			3,177
Total liabilities		2,009,120			2,635,706
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY:
Common stock, no par value; 50,000,000 shares authorized, 2,454,116 shares outstanding		4,650,812			4,633,655
Retained earnings		2,083,406			1,266,987
Total stockholders' equity		6,734,218			5,900,642
Total liabilities and stockholders' equity	$	8,743,338		$	8,536,348

LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Income (Unaudited)

	Three Months Ended September 30,
REVENUES:	2021			2020
Product sales	$	1,855,308		$	1,502,034
Royalties		9,941			31,395
Rental income		22,239			21,639
Total		1,887,488			1,555,068
COST OF SALES		953,437			957,964
GROSS PROFIT		934,051			597,104
OPERATING EXPENSES:
Research and development		299,653			335,075
Sales and marketing		306,664			235,733
General and administrative		245,970			297,128
Total		852,287			867,936
OPERATING INCOME (LOSS)		81,764			(270,832	)
OTHER INCOME (EXPENSE):
Forgiveness of Paycheck Protection loan		471,347			—
Interest income		1,347			2,598
Interest expense		(13,568	)		(14,051	)
Total		459,126			(11,453	)
NET INCOME (LOSS) BEFORE PROVISION FOR TAXES		540,890			(282,285	)
BENEFIT FROM (PROVISION FOR) FEDERAL AND STATE INCOME TAXES		(18,230	)		69,519
NET INCOME (LOSS)	$	522,660		$	(212,766	)
NET INCOME (LOSS) PER SHARE, BASIC	$	0.21		$	(0.09	)
NET INCOME (LOSS) PER SHARE, DILUTED	$	0.21		$	(0.09	)
WEIGHTED AVERAGE SHARES, BASIC		2,454,116			2,454,116
WEIGHTED AVERAGE SHARES, DILUTED		2,501,034			2,454,116

LIFELOC TECHNOLOGIES, INC.
Condensed Statements of Income (Unaudited)

	Nine Months Ended September 30,
REVENUES:	2021			2020
Product sales	$	5,304,800		$	4,705,598
Royalties		56,157			123,527
Rental income		65,710			64,317
Total		5,426,667			4,893,442
COST OF SALES		3,063,321			3,190,193
GROSS PROFIT		2,363,346			1,703,249
OPERATING EXPENSES:
Research and development		873,498			814,457
Sales and marketing		751,266			837,077
General and administrative		852,998			978,056
Total		2,477,762			2,629,590
OPERATING INCOME (LOSS)		(114,416	)		(926,341	)
OTHER INCOME (EXPENSE):
Forgiveness of Paycheck Protection loans		936,444			—
Interest income		2,659			13,016
Interest expense		(40,629	)		(42,198	)
Total		898,474			(29,182	)
NET INCOME (LOSS) BEFORE PROVISION FOR TAXES		784,058			(955,523	)
BENEFIT FROM (PROVISION FOR) FEDERAL AND STATE INCOME TAXES		32,361			227,859
NET INCOME (LOSS)	$	816,419		$	(727,664	)
NET INCOME (LOSS) PER SHARE, BASIC	$	0.33		$	(0.30	)
NET INCOME (LOSS) PER SHARE, DILUTED	$	0.33		$	(0.30	)
WEIGHTED AVERAGE SHARES, BASIC		2,454,116			2,454,116
WEIGHTED AVERAGE SHARES, DILUTED		2,493,492			2,454,116

 Lifeloc Technologies, Inc.

Statements of Stockholders' Equity (Unaudited)

	Three Months Ended September 30,					Nine Months Ended September 30,
	2021		2020			2021		2020
Total stockholders' equity, beginning balances	$	6,211,558	$	6,309,746		$	5,900,642	$	6,792,221
Common stock (no shares issued during periods):
Beginning balances		4,650,812		4,635,727			4,633,655		4,603,304
Stock based compensation expense related to stock options		—		311			17,157		32,734
Ending balances		4,650,812		4,636,038			4,650,812		4,636,038
Retained earnings:
Beginning balances		1,560,746		1,674,019			1,266,987		2,188,917
Net income (loss)		522,660		(212,766	)		816,419		(727,664	)
Ending balances		2,083,406		1,461,253			2,083,406		1,461,253
Total stockholders' equity, ending balances	$	6,734,218	$	6,097,291		$	6,734,218	$	6,097,291

 LIFELOC TECHNOLOGIES, INC.

Condensed Statements of Cash Flows (Unaudited)

	Nine Months Ended September 30,
CASH FLOWS FROM OPERATING ACTIVITIES:	2021			2020
Net income (loss)	$	816,419		$	(727,664	)
Adjustments to reconcile net income (loss) to net cash provided from (used in) operating activities-
Forgiveness of Paycheck Protection loans		(936,444	)		—
Depreciation and amortization		206,222			270,984
Provision for doubtful accounts, net change		(49,000	)		3,899
Provision for inventory obsolescence, net change		(5,000	)		48,943
Deferred taxes, net change		12,927			(11,188	)
Reserve for warranty expense, net change		—			1,500
Stock based compensation expense related to stock options		17,157			32,734
Changes in operating assets and liabilities-
Accounts receivable		(27,465	)		119,722
Inventories		(82,991	)		(581,640	)
Income taxes receivable		175,369			(216,654	)
Prepaid expenses and other		(11,430	)		(49,059	)
Deposits and other		1,318			(89,453	)
Accounts payable		(103,279	)		(4,055	)
Customer deposits		3,080			(31,221	)
Accrued expenses		(71,780	)		(78,099	)
Deferred revenue		6,458			(12,723	)
Net cash provided from (used in) operating activities		(48,439	)		(1,323,974	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment		(64,254	)		(9,088	)
Patent filing expense		(661	)		(18,772	)
Net cash provided from (used in) investing activities		(64,915	)		(27,860	)
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments made on term loan		(1,328,625	)		(34,372	)
Proceeds from refinancing term loan		1,350,000			—
Cost of refinancing term loan		(18,156	)		—
Proceeds from Paycheck Protection loan (round 2)		471,347			465,097
Net cash provided from (used in) financing activities		474,566			430,725
NET INCREASE (DECREASE) IN CASH		361,212			(921,109	)
CASH, BEGINNING OF PERIOD		2,195,070			3,185,996
CASH, END OF PERIOD	$	2,556,282		$	2,264,887
SUPPLEMENTAL INFORMATION:
Cash paid for interest	$	39,815		$	41,384
Cash paid for income tax	$	—		$	20,063